Skip to main content
Premium Trial:

Request an Annual Quote

Exelixis to Use Invitrogen s Assays for Drug Discovery

NEW YORK, Aug 12 (GenomeWeb News) - Invitrogen said today that it will provide Exelixis with validated high-throughput screening assays for drug discovery in single live cells, which Exelixis will use for lead discovery and optimization.


Carlsbad, Calif.-based Invitrogen said that its Drug Discovery Solutions group would provide Exelixis with its GeneBlazer and Voltage Sensor Probe technologies for compound screening. The GeneBlazer cell-based beta-lactamase system combines molecular and cellular biology with a fluorescence resonance energy transfer-based detection method for high-throughput screening experiments.


Invitrogen recently announced that the GeneBlazer and Voltage Sensor Probe technologies would be available for purchase by researchers without a licensing agreement.

The Scan

Dropped Charges

The US Justice Department has dropped visa fraud charges against five Chinese researchers, according to the Wall Street Journal.

More Kids

The Associated Press says Moderna is expanding its SARS-CoV-2 vaccine study to included additional children and may include even younger children.

PNAS Papers on Rat Clues to Human Migration, Thyroid Cancer, PolyG-DS

In PNAS this week: ancient rat genome analysis gives hints to human migrations, WDR77 gene mutations in thyroid cancer, and more.

Purnell Choppin Dies

Purnell Choppin, a virologist who led the Howard Hughes Medical Institute, has died at 91, according to the Washington Post.